WO1984004917A1 - 7-fluoroprostaglandines et leur procede de preparation - Google Patents
7-fluoroprostaglandines et leur procede de preparation Download PDFInfo
- Publication number
- WO1984004917A1 WO1984004917A1 PCT/JP1984/000294 JP8400294W WO8404917A1 WO 1984004917 A1 WO1984004917 A1 WO 1984004917A1 JP 8400294 W JP8400294 W JP 8400294W WO 8404917 A1 WO8404917 A1 WO 8404917A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- hydrogen atom
- represented
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
- C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to novel 7- year-old proprostaglandins and a method for producing the same.
- the present invention relates to a basically known 7-full-year prostaglandin using the novel 7-full-year prostaglandins.
- 1 class 2 novel production methods are also Oh Ru since about 0 back one scene technology of
- R 1Q in OR 12 is a hydrogen atom or an alkyl group having 1 to 10 carbon atoms
- R 11 and R 12 are each a hydrogen atom or the same or different protecting group
- R 5 is a linear or branched alkyl group, Where oz represents 1 to 1 attached to a carbon atom in the above formula C10.
- the number 15 represents the position of the carbon atom.
- Natural blanking Russia scan tag run-di down 1 Category 2 [hereinafter compound also include: you have a PGI 2) is chemically unstable and was neutral or is intends handled collected under the conditions of weakly acidic but and this is Ru difficult der, 7 represented by the above formula I0 - full O Russia profile scan tag run-di down 1 Category 2 is Oh stable also extremely under the conditions described above, or ⁇ of action o this 7 in terms of improved selectivity that have been considered to be useful - full silo profile scan tag run-di down 1 Category 2 7 - Non-mud key sheet PGrI of 2 full Tsu See Japanese Unexamined Patent Publication No. 57-16653 / 82 and Japanese Unexamined Patent Publication No. However, these methods have various problems such as low selectivity and yield, and too complicated reaction steps. Problem solved was desired o
- the present invention is 7 - full silo profile scan tag run-di down 1 2 such as an intermediate useful off Tsu fluorinated been new profile scan tag run-in for the preparation of Gins and their production methods.
- the present invention is basically known as described above, which is characterized in that the novel 7-fluoroprostaglandins are used as intermediates.
- the present invention relates to a method for producing a 7-fluoroglobulin staglandin 12 class.
- 7-PPGPP is a compound represented by the following formula [ ⁇ ].
- R 1 is water
- the number 15 represents the position of the carbon atom.
- the present invention also provides a 7-hydroxy (or trimethylsiloxy) brostagranzine (hereinafter referred to as) represented by the following formula:
- the present invention relates to a method for producing 7-F PGF represented by the above formula [I] by fluorinating and, if desired, deprotecting and / or hydrolyzing.
- ⁇ ⁇ is an alkyl group having 1 to ⁇ 0 carbon atoms
- f 7 , R 3 and R 9 are the same or different.
- the present invention is the above formula 7 represented by (I) - PPGF 3 ⁇ 4 characterized that you use via ⁇ reaction 7 represented by the following formula [II] - full silo profile scan tag run-di emissions 1 class 2 (or can the R 1 G is Ru water atom der its non-toxic salts) to produce the 7 - full silo blanking port scan tag run-di emissions Ru Nodea also about 1 class 2 novel process for the preparation of.
- R 1 is particularly preferably a methyl group or an ethyl group
- oi 2 and R 3 are the same or different protecting groups. Is preferred.
- the protecting group a trialkylsilyl group (three alkyl groups may be the same or different :), alkano Tylhydryl, tetrahydrovinyl, tetrahydrofuran ninyl, benzoyl, methoxhetoxyl, etc.
- R 6 is the same alkyl group as ⁇
- ⁇ ,, and R 9 are the same protecting groups as ⁇ 2 , I 3 , and ⁇ .
- R 8 and R 9 may be a trimethylsilyl group, but if they are trimethylsilyl groups, they may be trimethylsilyl groups.
- Application Benefits methylation Shi Li le old key Shimotoka s full Tsu Moti ⁇ in Tsu by the possibility of such stomach is Ashi ⁇ in full Tsu atom albeit stomach ⁇ especially in R 5 mosquitoes were click mouth a Le key Le group field, the I Ru 7 force s Application Benefits main Chi le Shi Li Le group der, 7 - FP X force yield is one good ⁇ decrease in GF
- Application Benefits main Chi le Shi Li In the case of a benzyl group, and R 9 are preferably a protecting group other than a trimethylsilyl group.
- R 8 , R 3 , and 1 may be common protecting groups, and similarly for R 9 and R i2 .
- R 3 is a protecting group, and then R 3 is converted to a hydrogen atom.
- O 7-XPGP £ D 7-FPGI 2 7 is preferably a protecting group different from H 8 and R 10 o Why must be converted to a hydrogen atom on the way, but ⁇ 8 is the last protecting group ⁇ 7 and this Ru der is Oh Ru ⁇ and follow in poetry, et al favored by the yield of the reaction is Shi preferred is a Ru easy protection 'Motodea this is also de-protected ⁇ 8 your good beauty R 9 nights Ku, in particular door re-ethyl Le Shi Shi preferred and Li Le Motodea Ru this is ⁇ - how, H S and R 9 is other than the door Li main Chi Le Shi Li Le based on'm beauty door Li E Chi Le Shi Li Le based on They are
- a Le key Le group 3 ⁇ 4 of 3 or more carbon atoms protecting group is suitably Dea, especially di main Chi le - t - Bed Chi le arbitrarily 0 preferred is Li Le group
- the n-amyl group or the pentopenyl group is preferable.
- the 7 - PPGI 2 new Der wherein the known example does not describe o ft 5 starve click port Bae
- the yield of is very low.o is a linear or branched (i.e., in the case of a non-cyclic alkyl group, in the fluorination of sweet high Ru Ku has [Nandea coma and this exceeds the yield 5 ⁇ ) o against thereto, 7 - when X is Application Benefits main Chi le Shi Li Le group, forces force the kind of R 5
- the yield of 7 -FPGF is high, exceeding about 60, and it is
- X is a trimethylsilyl group.
- alcoholic hydroxyl groups are fluorinated with a fluorinating agent. It is well known that nitrogen is substituted by a fluorine atom.
- a trimethylsilyl group i.e., one OS i (_CH 3 ) The substitution of a fluorine atom by fluorination of 3 ) with a fluorinating agent has been found for the first time by the present inventors.
- O Trimethyl Trialkylsilyl groups other than silyl groups are inert to fluorination and cannot be replaced with fluorine atoms. o ⁇
- Preferred as 7-represented by the formula (I) are the following compounds o
- the following 15-cyclopentyl PGF 2 ⁇ derivative is a PGP 2A derivative having no ⁇ -amyl group at the 15th position, ie, 16,
- the fluorination of 7-XP GF represented by the formula) is basically performed by a known method.o The fluorination is usually carried out by dissolving in a solvent.
- OMPI Is the o off Tsu fluorinated agent rope line by the and the child to make a full Tsu fluorinated agent in the solution R 13 N-SF 3 [R 13: even though the oxygen 3 ⁇ 4 Yes having a carbon number of 4 to 7 Bubble ring 3 ⁇ 4 formed hydrocarbon group :) or D15 ⁇ N -SF 3 [, R 15 : same or
- the preferred fluorinating agents are piperidinol salfate-rich rides, etc. Nosulfur trifluoride; Ride-type fluorine-containing tj o Aminosulfur trifluoride as a fluorinating agent
- a fluorinating agent when X is a hydrogen atom, it is preferable to use a base in combination, for example, pyridin, triethylamine, dimethine.
- X can be used 0
- X is a trimethylsilyl group
- fluorination occurs when a base is present 0
- Halogenated hydrocarbons such as salt, methylene, dichloromethan, chloromethane, carbon tetrachloride, benzene and toluene.
- hydrocarbons, tetrahydrofuran, ethers such as various alkyl ethers, and other solvents ⁇
- the reaction temperature is 110 ⁇ t; 50 C is appropriate.
- the product obtained by the above method is as desired.] Perform deprotection and hydrolysis.
- the protecting group is a trialkylsilyl group
- deprotection is carried out using tetraalkylammonium, such as tetrabutylammonamide. ⁇ It is appropriate to use the multi-purpose rider o Tetra trial
- -Palladium fluoride can be used in combination with a base such as trialkylamine.
- O Solvents such as tetrahydrofuran Ether is appropriate o
- the protecting group is an acyl group, etc.
- deprotection is appropriate by hydrolysis with alkyl alcohol o ', and fi 1 is an alkyl group
- the same alcohol hydrolysis can be converted to a hydrogen atom.
- Alkali hydrolysis can be sodium hydroxide, hydration power, and other alcohols.
- the production of 7-FPG "I 2 represented by the formula [I] is carried out by subjecting the compound represented by the formula [I] to a cyclization reaction.
- the hydroxyl group at the 9-position represented by the formula (I) has been deprotected. That is, it is preferable that R 2 is a hydrogen atom) or a alkyl group.
- the basic reaction of cyclization is well known] 9, and is described in "J-Amer. Chera Soc.”, Vol. 104, pp. 5842-5844 [1982].
- 7 - JP P 1 2 is or or a R 10 force A Le key group, changing the by R 10 in the hydrolysis was or a hydrogen atom, if there is a protecting group I line deprotection, known Same as 7-FPGI 2.
- R 1Q is a hydrogen atom
- 7-FPGI 2 reacts with various bases to form a non-toxic salt, This can be used as a medicine.
- the base may be a hydroxide of alkaline metal, a hydroxide, a carbonate of alkaline earth metal, a hydroxide of alkaline earth metal, ammonia, mono or alkali. It is appropriate to use normal or o
- a feature of the present invention is that the use of the preferred fluorinating agent causes the fluorination of the carbon atom at the 7-position to occur at an extremely high selectivity, resulting in an extremely high yield. .
- the reason for this is that This is probably because the xy group is adjacent to a carbon atom having a triple bond (carbon atom at position 6 ) and is activated. For example, if the 5- and 6- positions are a double bond or a single bond, the elimination reaction will give priority to the formation of the olefin and the yield will be extremely low.
- R 5 , R 6 , _R 3 , and R 9 are the same as those in formula [II].
- a trimethylsilyl group is introduced into the 7th hydroxyl group, and the 9th hydroxyl group is a trimethylsilyl group due to the difference in reactivity between the two hydroxyl groups. And can be carried out under difficult conditions.
- 7-XP GF in which X is a trimethylsilyl group can be obtained.
- Application Benefits main Chi le sheet by only re Le group and this deprotection is a hydroxyl group 7 - are obtained.
- ⁇ X is a trimethylsilyl group 7-XF G F is obtained o
- R 5 is an n-amyl group
- R 3 is a methyl group
- R 8 and R 9 are dimethyl-t-butyl-butyryl groups.
- Trimethylsilyldiethyl amide 490 ⁇ C2.59mo1 was added dropwise to the solution (C 8MS) at 140 C, and the mixture was stirred under the same conditions for 2 hours. 0 Pour the mixture into an ice-cooled saturated aqueous solution of sodium hydrogen carbonate (2 ⁇ m £) and pour the aqueous layer twice with ethyl ether (107 7).
- 7 - FPGP will have a -A o 13 C -NMRCCDC 1 3, TMS, ppm): 5 6 1. 5 CC - 7), 7 2. 5 C - 1 1), 7 3. 2 CC - 1 5) , 7 7.2 CC-9)
- THP acetic acid-tetrahydrofuran
- water 8: 8: 1 A mixture of acetic acid-tetrahydrofuran (hereinafter referred to as THP) -water 8: 8: 1) is placed in a reaction vessel containing the above product 25 3 C 0.319 771 moi).
- THP acetic acid-tetrahydrofuran
- 3.2 Addition at ⁇ C o
- low-boiling components were reduced at 0 C.
- ⁇ Residues were added with ethyl ⁇ 1 1 1 m and saturated hydrogen peroxide
- the water station was extracted three times with ether (C 5 ⁇ £) using 10 sodium aqueous solution. Washed with organic saline solution, dried with magnesium sulfate anhydride and reduced and then compressed.
- Example 7 The compound obtained in Example 7 was subjected to a cyclization reaction by the method of Example 3 to obtain a compound having a 7-phenylene-15-cyclopentanoline PG "I2methylenol PG" Estenole L1, I5-vis C dimethyl-t-butyl) Manufacture of silyl ether o According to the ram chromatograph Later yield was 74 ⁇ .
- R 5 is a cyclopentyl group
- R 6 is a methyl group
- R 3 and R 9 are dimethyl-t-butylsilyl groups
- the R-113 solution of the above-mentioned product was mixed with a pyridinosulfone trifluoride (58, 0.58 mmo IJ).
- Triol which is the final product of Example 11, was cyclized.
- triethylamine 85 ⁇ C 0.608-71 mo 1) cool at 178 C, and hydrate sodium borohydride 1 15 (3.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE8484902214T DE3483314D1 (de) | 1983-06-10 | 1984-06-07 | 7-fluorprostaglandine und deren herstellungsverfahren. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58102885A JPS59227888A (ja) | 1983-06-10 | 1983-06-10 | 7−フルオロプロスタグランジン類の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1984004917A1 true WO1984004917A1 (fr) | 1984-12-20 |
Family
ID=14339318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1984/000294 Ceased WO1984004917A1 (fr) | 1983-06-10 | 1984-06-07 | 7-fluoroprostaglandines et leur procede de preparation |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4699989A (https=) |
| EP (1) | EP0148953B1 (https=) |
| JP (1) | JPS59227888A (https=) |
| DE (1) | DE3483314D1 (https=) |
| WO (1) | WO1984004917A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3740596A1 (de) * | 1986-12-01 | 1988-06-16 | Hoffmann La Roche | Neue prostacycline |
| US9006291B2 (en) | 2009-02-03 | 2015-04-14 | Pharma Patent Holding Inc. | Composition, method and kit for enhancing hair |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680415A (en) * | 1985-06-24 | 1987-07-14 | Hoffmann-La Roche Inc. | Intermediates for 7-fluoro dihydro PGI compounds |
| US4634782A (en) * | 1985-06-24 | 1987-01-06 | Hoffmann-La Roche Inc. | 7-fluoro-dihydro PGI compounds |
| CH674363A5 (https=) * | 1986-12-01 | 1990-05-31 | Hoffmann La Roche | |
| JPH01102059A (ja) * | 1987-10-16 | 1989-04-19 | Asahi Glass Co Ltd | 6−フルオロプロスタグランジン誘導体 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS525740A (en) * | 1975-06-26 | 1977-01-17 | Syntex Inc | New prostaglandin homologs and process for manufacture thereof |
| JPS57165382A (en) * | 1981-04-06 | 1982-10-12 | Teijin Ltd | Fluoro-pgi2 compound and its preparation |
| JPS57171988A (en) * | 1981-03-11 | 1982-10-22 | Hoffmann La Roche | Novel fluoroprostacyclins |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634782A (en) * | 1985-06-24 | 1987-01-06 | Hoffmann-La Roche Inc. | 7-fluoro-dihydro PGI compounds |
-
1983
- 1983-06-10 JP JP58102885A patent/JPS59227888A/ja active Granted
-
1984
- 1984-06-07 EP EP84902214A patent/EP0148953B1/en not_active Expired - Lifetime
- 1984-06-07 US US06/702,790 patent/US4699989A/en not_active Expired - Fee Related
- 1984-06-07 DE DE8484902214T patent/DE3483314D1/de not_active Expired - Lifetime
- 1984-06-07 WO PCT/JP1984/000294 patent/WO1984004917A1/ja not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS525740A (en) * | 1975-06-26 | 1977-01-17 | Syntex Inc | New prostaglandin homologs and process for manufacture thereof |
| JPS57171988A (en) * | 1981-03-11 | 1982-10-22 | Hoffmann La Roche | Novel fluoroprostacyclins |
| JPS57165382A (en) * | 1981-04-06 | 1982-10-12 | Teijin Ltd | Fluoro-pgi2 compound and its preparation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3740596A1 (de) * | 1986-12-01 | 1988-06-16 | Hoffmann La Roche | Neue prostacycline |
| US9006291B2 (en) | 2009-02-03 | 2015-04-14 | Pharma Patent Holding Inc. | Composition, method and kit for enhancing hair |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59227888A (ja) | 1984-12-21 |
| EP0148953A4 (en) | 1985-09-26 |
| EP0148953B1 (en) | 1990-09-26 |
| DE3483314D1 (de) | 1990-10-31 |
| JPS6343385B2 (https=) | 1988-08-30 |
| US4699989A (en) | 1987-10-13 |
| EP0148953A1 (en) | 1985-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1984004917A1 (fr) | 7-fluoroprostaglandines et leur procede de preparation | |
| CN1122039C (zh) | 还原前手性酮以制备高光学纯度的光活性醇的方法 | |
| RU2056402C1 (ru) | Способ получения гидрата трифторацетальдегида | |
| JPS5995231A (ja) | 光学活性化合物の製造方法 | |
| JPH0572387B2 (https=) | ||
| JP3631070B2 (ja) | 光学活性含弗素ビナフトール誘導体 | |
| JP2000143688A (ja) | ゼアキサンチンモノ−β−グルコシドの製造方法 | |
| JP5305697B2 (ja) | α−D−マンノピラノシド誘導体の製造方法 | |
| JP2018052831A (ja) | フッ素化炭化水素の製造方法 | |
| CN113825759A (zh) | 美登醇的制备 | |
| JPS5931754A (ja) | 治療効果を有する新規〔3.2.0〕ビシクロヘプタノンオキシムエ−テル | |
| JP2522926B2 (ja) | 2′−デオキシ−5−トリフルオロメチルウリジン誘導体の製造方法 | |
| WO1996026891A1 (en) | Substituted cyclopentene derivatives and process for the preparation thereof | |
| JPS6234025B2 (https=) | ||
| CN108137457B (zh) | 苯氧乙醇衍生物的制造方法 | |
| JP3266701B2 (ja) | 2,3−ジヒドロポリプレノールの製造法 | |
| JPH0761979A (ja) | ビスフェノール誘導体及びその製造方法 | |
| JP2975705B2 (ja) | ステロイド誘導体 | |
| KR100570279B1 (ko) | 코엔자임 Qn의 중간체 및 그 중간체의 제조방법 | |
| CN100582094C (zh) | 3,4,5-三羟基哌啶生物碱的制备方法 | |
| JP3473053B2 (ja) | アセチレンアルコール類の製造法 | |
| JP2014105182A (ja) | エーテル化合物製造法 | |
| JPH0529237B2 (https=) | ||
| JPS632251B2 (https=) | ||
| JPS63211292A (ja) | プロスタグランジン類 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Designated state(s): HU US |
|
| AL | Designated countries for regional patents |
Designated state(s): CH DE FR GB |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1984902214 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1984902214 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1984902214 Country of ref document: EP |